RCUS vs. ANIP, KNSA, DAWN, XNCR, MORF, PTGX, AKRO, GMTX, LGND, and DVAX
Should you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include ANI Pharmaceuticals (ANIP), Kiniksa Pharmaceuticals (KNSA), Day One Biopharmaceuticals (DAWN), Xencor (XNCR), Morphic (MORF), Protagonist Therapeutics (PTGX), Akero Therapeutics (AKRO), Gemini Therapeutics (GMTX), Ligand Pharmaceuticals (LGND), and Dynavax Technologies (DVAX). These companies are all part of the "pharmaceutical preparations" industry.
ANI Pharmaceuticals (NASDAQ:ANIP) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership.
In the previous week, Arcus Biosciences had 3 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 20 mentions for Arcus Biosciences and 17 mentions for ANI Pharmaceuticals. Arcus Biosciences' average media sentiment score of 0.75 beat ANI Pharmaceuticals' score of 0.54 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.
ANI Pharmaceuticals received 243 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 64.59% of users gave ANI Pharmaceuticals an outperform vote while only 64.54% of users gave Arcus Biosciences an outperform vote.
ANI Pharmaceuticals presently has a consensus price target of $80.00, indicating a potential upside of 17.56%. Arcus Biosciences has a consensus price target of $41.25, indicating a potential upside of 147.01%. Given ANI Pharmaceuticals' higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than ANI Pharmaceuticals.
76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
ANI Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.
ANI Pharmaceuticals has a net margin of 3.86% compared to ANI Pharmaceuticals' net margin of -262.39%. Arcus Biosciences' return on equity of 18.06% beat ANI Pharmaceuticals' return on equity.
ANI Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
ANI Pharmaceuticals beats Arcus Biosciences on 12 of the 18 factors compared between the two stocks.
Get Arcus Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcus Biosciences Competitors List
Related Companies and Tools
